Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today...